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Background: Hypertension is a serious global public health problem. 
It accounts for 10% of all deaths in India and is the leading noncom-
municable disease.1 Recent studies have shown that the prevalence 
of hypertension is 25% in urban and 10% in rural people in India.2 
It exerts a substantial public health burden on cardiovascular health 
status and health care systems in India.3 Antihypertensive treatment 
effectively reduces hypertension-related morbidity and mortality.1 
The cost of medications has always been a barrier to effective treat-
ment. The increasing prevalence of hypertension requires use of cost-
effective treatment for the effective management of the disease.
Objectives: The present study assesses the cost-effectiveness of anti-
hypertensive drugs in patients with hypertension from Mumbai, 
India.
Methods: A prospective cross-sectional study was conducted to 
assess the cost-effectiveness of antihypertensive drugs. Face-to-face 
interviews were conducted by using a validated questionnaire in a 
total of 136 (66 males, 70 females) patients with hypertension from 
F-North Ward, Mumbai, India. Cost-effectiveness was determined 
on the basis of a drug’s cost, efficacy, adverse drug reactions, safety 
of administration, frequency of administration, and bioavailability.
Results: Atenolol was most cost-effective (international normalized 
ratio [INR]: 5.5/unit of effectiveness), followed by the amlodipine 
+ losartan combination (INR: 5.6/unit of effectiveness) and amlodi-
pine (INR: 6.3/unit of effectiveness) in the present study. Thirty-eight 
(28%) patients received combination therapy. Lisinopril prescribed 
to16 (11.8%) patients was the least cost-effective drug (INR: 17.2/unit 
of effectiveness).
Conclusions: Prescriptions of cost-effective antihypertensive drugs 
(73.5%) were more common than less cost-effective antihypertensive 
drugs (26.5%) in hypertensive patients from Mumbai, India. Most 
of the patients (72%) were prescribed monotherapy in the treatment 
of hypertension.
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